PARTNERS

WHAM’s research is encouraged through the generous support from the following partners and collaborators:

PLATINUM PARTNERS

KPMG Foundation

The KPMG U.S. Foundation seeks to create a world with equity and access to opportunity for all.

Building on our firm’s 125 years of positive impact in the communities where we live and work, KPMG U.S. and the KPMG U.S. Foundation are committing more than $125 million over the next five years to support programs that will help underrepresented groups confront systemic barriers in education, health care, and economic opportunity.

Northwell Health

As the largest health system in New York, Northwell is dedicated to raising the standard of health care for all. Northwell Health knows women’s health issues are very often misdiagnosed, mistreated, or sometimes just plain missed altogether. That’s why, fueled by the vision of Iris and Saul Katz, Northwell created the Katz Institute for Women’s Health. the only network of experts devoted to every aspect of women’s care.

At Northwell, women’s health expertise doesn’t end at gynecology and breast health. Northwell’s Katz Institute for Women’s Health is dedicated to improving the health of women across their lifespan, bridging the gap between wellness and personalized care delivery.  ​KIWH is advancing women’s health every day by providing expert, coordinated clinical care, educating our community on prevention and well-being and supporting sex- and gender-specific research. Because when we raise the health of women, we raise everyone.

PARTNERS & COLLABORATORS

American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives dedicated to ensuring equitable health for all—in the United States and around the world. The American Heart Association’s signature women’s initiative, Go Red for Women® (GRFW), has been the trusted, passionate, relevant force for change to end heart disease and stroke in women all over the world for nearly two decades. GRFW and WHAM will collaborate to directly address the lack of societal-level evidence on the economic cost, benefits, and social impact due to the underrepresentation of women in cardiovascular research.

BrightFocus Foundation

BrightFocus Foundation is a leading source of private research funding to defeat Alzheimer’s, macular degeneration and glaucoma. Supporting scientists early in their careers to kick-start promising ideas, BrightFocus addresses a full and diverse range of approaches from better understanding the root causes of the diseases and improving early detection and diagnosis, to developing new drugs and treatments. The nonprofit has a longstanding commitment to funding pioneering, sex-based research in Alzheimer’s and related dementias. BrightFocus currently manages a global portfolio of over 275 scientific projects, a $60 million investment, and shares the latest research findings and best practices to empower families impacted by these diseases of mind and sight.

Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital, Harvard Medical School

Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital, Harvard Medical School is a leading local and national force in advancing the health of women, with a rich history and strong foundation of women’s health and sex-differences discovery, clinical care, and advocacy for equity in the health of women and is the Premier Partner and the Lead Scientific Research Partner of the WHAM Collaborative for Women’s Health Research. The Connors Center shares the bold vision of improving the health of women and a commitment to joining forces to advance scientific discovery for the benefit of all women.

GO2 for Lung Cancer

GO2 for Lung Cancer (GO2) relentlessly confronts lung cancer on every front, every day. Founded by patients and survivors, GO2 is dedicated to increasing survival for those at risk, diagnosed and living with lung cancer. GO2 serves as the “go-to” for assistance across the care continuum and is the source for improving health policies and leading public awareness to shift the disease away from stigma to hope. The Women and Lung Cancer Research and Preventive Service Act provides a foundation for WHAM and GO2 to engage in strong partnership to advance our shared goal of improving health outcomes for women.

La Jolla Institute for Immunology

La Jolla Institute (LJI) is one of the top five research institutes in the world focused on the study of the immune system. LJI is home to three research centers that harness the efforts of collaborative groups of researchers on defined areas of inquiry, to accelerate progress toward the development of new treatments and vaccines to prevent and cure autoimmune conditions, cancer and infectious disease. Together, LJI and WHAM will create a framework for researchers to re-analyze existing data with sex as a biological variable, to work together to spark new projects, to hire new faculty to build key research areas, to communicate via the WHAM Report, and to establish an ignition point for new leadership in the scientific field.

RAND Corporation

WHAM commissioned The RAND Corporation in 2020 to conduct a data-driven study of the economic impact to society of increasing the investment in women’s health research. This first research project comprises four disease modules: Alzheimer’s disease, rheumatoid arthritis as representative of autoimmune disease, coronary artery disease and lung cancer. In the future, we plan to expand our research to include global data and other conditions which predominantly, exclusively or differentially affect women.

To the best of WHAM’s and RAND’s knowledge, this is the first analysis of its kind to create and calibrate a microsimulation model of investments in health R&D that examines differences for women’s health research investment and should become a seminal part of the arsenal in advocating for increased investment in women’s health research. The research methodology and the microsimulation models have been vetted by a diverse panel of experts convened by RAND.

Walgreens

Walgreens is revolutionizing the landscape of clinical trials by leveraging its extensive community presence, patient accessibility, and consumer trust. Through their initiative, Walgreens Clinical Trials, they aim to democratize participation in clinical research, especially for the 78% of Americans living near a Walgreens store. With a dedicated research team collaborating with leading institutions, they’ve facilitated over 35 contracts with pharmaceutical companies, such as Prothena Biosciences and Freenome. Notably, their outreach efforts have engaged over 4.5 million individuals across the nation, resulting in a diverse pool of participants, with nearly half coming from historically underserved populations, in stark contrast to the predominantly white makeup of US clinical trial participants in recent years.

Thank you to everyone who contributed to the creation of the WHAM 3Not30 Goals to accelerate women’s health research and investment in the next three years:

We appreciate the following organizations who joined us in supporting the WHAM-backed Resolution in Congress in May 2022 to expand women’s health research.